Oncolytic viruses (OVs) are promising for cancer treatment as they specifically replicate in tumor cells. However, the systemic delivery of OVs still faces the challenges of poor tumor targeting, short circulation periods, and limited lytic efficacy. Herein, an OV-concealed targeting nanoagonist (OV-MnO